ERRATUM: Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad (Endocrine-Related Cancer 21:part 4 (567–577) DOI: 10.1530/ERC-14-0254) (2025) Haller F, Moskalev E, Faucz FR, Barthelmeß S, Wiemann S, Bieg M, Assie G, et al. Journal article, Erratum Improved pasireotide response in USP8 mutant corticotroph tumours in vitro (2022) Albani A, Perez-Rivas LG, Tang S, Simon J, Lucia KE, Colón-Bolea P, Schopohl J, et al. Journal article Targeted inhibition of the WEE1 kinase as a novel therapeutic strategy in neuroendocrine neoplasms (2021) Weindl L, Atreya I, Dietrich P, Neubeck S, Neurath M, Pavel ME Journal article Treatment outcomes of advanced digestive well-differentiated grade 3 NETs (2021) de Mestier L, Lamarca A, Hernando J, Zandee W, Alonso-Gordoa T, Perrier M, Walenkamp AM, et al. Journal article Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms (2021) Yao JC, Strosberg J, Fazio N, Pavel ME, Bergsland E, Ruszniewski P, Halperin DM, et al. Journal article Gastric neuroendocrine neoplasias: manifestations and comparative outcomes (2019) Felder S, Jann H, Arsenic R, Denecke T, Prasad , Knappe-Drzikova B, Maasberg S, et al. Journal article Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials (2019) Yao J, Garg A, Chen D, Capdevila J, Engstrom P, Pommier R, Van Cutsem E, et al. Journal article SHH pathway inhibition is protumourigenic in adamantinomatous craniopharyngioma (2019) Carreno G, Boult JKR, Apps J, Gonzalez-Meljem JM, Haston S, Guiho R, Stache C, et al. Journal article Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial (2018) Pavel ME, Gross DJ, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, Kulke MH, et al. Journal article T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly (2016) Potorac I, Petrossians P, Daly AF, Alexopoulou O, Borot S, Sahnoun-Fathallah M, Castinetti F, et al. Journal article